Pharmacophor requirements of the aldose reductase inhibitor site

P. F. Kador, N. E. Sharpless

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Recent experimental results suggesting that diabetic pathology can at least in part be directly controlled through inhibition of the enzyme aldose reductase (alditol: NADPH oxidoreductase, EC 1.1.21) have spurred great interest in the development of specific inhibitors of this enzyme. Specific structural and electronic similarities of apparently diverse aldose reductase inhibitors have been observed through basic studies which utilize computer molecular modeling, molecular orbital calculations, known structure-activity relationships, and protein-modifications reagents such as 2-bromo-4'-nitroacetophenone. From these similarities, a model of the aldose reductase inhibitor site has been postulated along with the pharmacophor requirements for the inhibitors - guideliness which should aid in the rational design of new inhibitors.

Original languageEnglish (US)
Pages (from-to)521-531
Number of pages11
JournalMolecular pharmacology
Volume24
Issue number3
StatePublished - Dec 1 1983

Fingerprint

Aldehyde Reductase
Molecular Computers
Sugar Alcohols
Enzyme Inhibitors
Structure-Activity Relationship
NADP
Oxidoreductases
Pathology
Enzymes
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Pharmacophor requirements of the aldose reductase inhibitor site. / Kador, P. F.; Sharpless, N. E.

In: Molecular pharmacology, Vol. 24, No. 3, 01.12.1983, p. 521-531.

Research output: Contribution to journalArticle

@article{fca56c1afbda4160953adeec8182edc5,
title = "Pharmacophor requirements of the aldose reductase inhibitor site",
abstract = "Recent experimental results suggesting that diabetic pathology can at least in part be directly controlled through inhibition of the enzyme aldose reductase (alditol: NADPH oxidoreductase, EC 1.1.21) have spurred great interest in the development of specific inhibitors of this enzyme. Specific structural and electronic similarities of apparently diverse aldose reductase inhibitors have been observed through basic studies which utilize computer molecular modeling, molecular orbital calculations, known structure-activity relationships, and protein-modifications reagents such as 2-bromo-4'-nitroacetophenone. From these similarities, a model of the aldose reductase inhibitor site has been postulated along with the pharmacophor requirements for the inhibitors - guideliness which should aid in the rational design of new inhibitors.",
author = "Kador, {P. F.} and Sharpless, {N. E.}",
year = "1983",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
pages = "521--531",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Pharmacophor requirements of the aldose reductase inhibitor site

AU - Kador, P. F.

AU - Sharpless, N. E.

PY - 1983/12/1

Y1 - 1983/12/1

N2 - Recent experimental results suggesting that diabetic pathology can at least in part be directly controlled through inhibition of the enzyme aldose reductase (alditol: NADPH oxidoreductase, EC 1.1.21) have spurred great interest in the development of specific inhibitors of this enzyme. Specific structural and electronic similarities of apparently diverse aldose reductase inhibitors have been observed through basic studies which utilize computer molecular modeling, molecular orbital calculations, known structure-activity relationships, and protein-modifications reagents such as 2-bromo-4'-nitroacetophenone. From these similarities, a model of the aldose reductase inhibitor site has been postulated along with the pharmacophor requirements for the inhibitors - guideliness which should aid in the rational design of new inhibitors.

AB - Recent experimental results suggesting that diabetic pathology can at least in part be directly controlled through inhibition of the enzyme aldose reductase (alditol: NADPH oxidoreductase, EC 1.1.21) have spurred great interest in the development of specific inhibitors of this enzyme. Specific structural and electronic similarities of apparently diverse aldose reductase inhibitors have been observed through basic studies which utilize computer molecular modeling, molecular orbital calculations, known structure-activity relationships, and protein-modifications reagents such as 2-bromo-4'-nitroacetophenone. From these similarities, a model of the aldose reductase inhibitor site has been postulated along with the pharmacophor requirements for the inhibitors - guideliness which should aid in the rational design of new inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0021027160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021027160&partnerID=8YFLogxK

M3 - Article

C2 - 6415401

AN - SCOPUS:0021027160

VL - 24

SP - 521

EP - 531

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -